Cargando…
Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
BACKGROUND: Significant advances in the pharmacologic treatment of psoriasis,most notably the introduction of the biologic agents efalizumab and alefacept,have occurred recently. In addition, another biologic agent, etanercept, was recently approved for the treatment of psoriasis and psoriatic arthr...
Autor principal: | Fisher, Vicki S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437546/ https://www.ncbi.nlm.nih.gov/pubmed/15667232 http://dx.doi.org/10.18553/jmcp.2005.11.1.33 |
Ejemplares similares
-
Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
por: Campbell, Helen Eloise
Publicado: (2005) -
Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010) -
Effect of Patient Notification of Formulary Change on Formulary Adherence
por: Delate, Thomas, et al.
Publicado: (2005) -
Clinical Monograph: Hormone Replacement Therapy
por: Deady, Joan
Publicado: (2004) -
The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)